Non-small cell lung cancer: From targeted therapy to tailored therapy

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 13, 2012, Pages 1817-1819

  Malgieri, Simona ^a   Feliciano, Salvatore ^a   Bosso, Davide ^a   Federico, Piera ^a   Palmieri, Giovannella ^a   De Placido, Sabino ^a   Di Lorenzo, Giuseppe ^a   Buonerba, Carlo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Bevacizumab; Lung cancer; Tailored therapy; Targeted therapy

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CRIZOTINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; IFOSFAMIDE; MITOMYCIN; NAVELBINE; PACLITAXEL; PLACEBO;

ADVANCED CANCER; ALOPECIA; BLEEDING; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DECISION MAKING; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; EMBOLISM; FATIGUE; HEMOPTYSIS; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; META ANALYSIS (TOPIC); NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICIAN; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; RISK; SOLID TUMOR; THROMBOCYTOPENIA; THROMBOSIS;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; LUNG NEOPLASMS; SURVIVAL RATE;

EID: 84865342131     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.707645     Document Type: Review

References (15)

1. Rapp E, Pater JL, Willan A, et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer-report of a Canadian multicenter randomized trial. J Clin Oncol 1988;6(4):633-41
2. Crino L, Tonato M, Darwish S, et al. A randomized trial for three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group. Cancer Chemother Pharmacol 1990;26(1):52-6 (Pubitemid 20122889)
3. Ettinger DS, Akerley W, Bepler G, et al. Non-small cell lung cancer. J Natl Compr Canc Netw 2010;8:740-801
4. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20(21):4285-91 (Pubitemid 35266288)
5. Schiller JH, Harrington D, Belani CP, Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346(2):92-8 (Pubitemid 34438899)
6. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-50 (Pubitemid 44917502)
7. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:1227-34
8. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009;373(9674):1525-31
9. Di Lorenzo G, Porta C, Bellmunt J, et al. Toxicities of targeted therapy and their management in kidney cancer. Eur Urol 2011;59(4):526-40
10. Hang XF, Xu WS, Wang JX, et al. Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 2011;67(6):613-23
11. Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 2011;305(5):487-94
12. Correale P, Remondo C, Carbone SF, et al. Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients. Cancer Biol Ther 2010;9(9):685-93
13. Correale P, Botta C, Basile A. Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients. Cancer Biol Ther 2011;12(2):112-18
14. Leon L, Vázquez S, Gracia JM, et al. First line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small-cell lung cancer chemo-naïve patients. Expert Opin Pharmacother 2012;13(10):1389-96
15. Dediu M. Should we discard vinorelbine plus cisplatin from the first-line therapy of advanced non-small-cell lung cancer? J Clin Oncol 2004;22(7): 1345-7; author reply 1347 (Pubitemid 41079856)